CCR4 and neoplasm: Indeed, the anti-CCR4 mAb mogamulizumab, which showed significant anti-tumor activity against ATL cells in the NOG mice via enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) [66], has been developed and subsequently approved for the treatment of relapsed or refractory ATL in Japan [67].